Dr. Denise Faustman, director of the Massachusetts General Hospital Immunobiology Laboratory in Boston, is very excited about the results the BCG vaccine has been showing.
“In the phase I (preliminary) trial we demonstrated a statistically significant response to BCG, but our goal in (this trial) is to create a lasting therapeutic response. We will be working again with people who have had type 1 diabetes for many years. This is not a prevention trial; instead, we are trying to create a regimen that will treat even advanced disease” explained Dr. Denise.
There’s a new trial coming which will use the same format as the previous one, on people at the age between 18 and 60. The subjects will be injected with the vaccine twice in a period of 4 weeks, and then once a year for a 4-year time span.
The Diabetes Care journal has published the results of a past study which analyzed the effects of Bacillus Calmette-Guerin (BCG) on kids with diabetes at the age between 5 and 18. The results showed that the BCG vaccine doesn’t keep the beta-cell function or raise the remission rate in kids.